Open AccessA Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy
Author(s) -
Deborah McMahon,
Zheng Li,
Joshua C. Cyktor,
Evgenia Aga,
Bernard Macatangay,
Catherine Godfrey,
Michael F. Para,
Ronald T. Mitsuyasu,
Joseph Hesselgesser,
Joan Dragavon,
Curtis Dobrowolski,
Jonathan Karn,
Edward P. Acosta,
Rajesh T. Gandhi,
John W. Mellors
Publication year - 2020
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiaa777
Subject(s) - placebo , medicine , viremia , romidepsin , viral load , pharmacodynamics , neutropenia , histone deacetylase inhibitor , cohort , gastroenterology , immunology , pharmacology , histone deacetylase , pharmacokinetics , human immunodeficiency virus (hiv) , biology , histone , chemotherapy , pathology , biochemistry , alternative medicine , gene
Romidepsin (RMD) is a histone deacetylase inhibitor reported to reverse HIV-1 latency. We sought to identify doses of RMD that were safe and induced HIV-1 expression.